Relapsed/Refractory Multiple Myeloma: Shared Care Between Cellular Therapy Centers and Community Oncology

Dr. Joshua Richter and Dr. Marco Davila discuss the importance of collaboration between specialized cellular therapy centers and community oncologists to improve access to CAR T-cell therapy for patients with relapsed/refractory multiple myeloma (RRMM). Dr. Davila explains that effective communication and coordinated care are essential for overcoming logistical barriers and ensuring patients can receive timely treatment while remaining connected to their local oncology team. He describes a shared care model in which patients return to their community oncologist soon after CAR T-cell therapy, with ongoing follow-up responsibilities divided between the referring physician and the cellular therapy center. The discussion highlights the value of structured communication, individualized referral pathways, and clear guidance regarding post-treatment monitoring for delayed toxicities and recovery. By fostering strong partnerships with community practices, the faculty emphasize that multidisciplinary collaboration can expand access to advanced therapies, enhance continuity of care, and improve the overall treatment experience for patients with RRMM.